TBPH — Theravance Biopharma Inc stock price, charts and financials

QT68Theravance Biopharma Inc

Theravance Biopharma Inc (NASDAQ: TBPH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.87
+0.01+0.06%
OverviewShort InterestFilings
TBPHQT68Theravance Biopharma Inc·NASDAQ
16.87+0.06%
TA
Loading chart...
Screen all →
IOVA+6.14%$4.32FTRE-1.20%$18.94SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E7.45EPS (ttm)2.26Insider Own31.55%Shs Outstand51.83MPerf Week0.00%
Market Cap873.82MForward P/E9.04EPS next Y1.86Insider Trans-0.27%Shs Float48.48MPerf Month-0.71%
Enterprise Value659.02MPEG0.00EPS next Q-Inst Own-Short Float8.88%Perf Quarter0.72%
Income115.78MP/S7.96EPS this Y20.71%Inst Trans-Short Ratio7.81Perf Half Y-12.10%
Sales109.77MP/B2.98EPS next Y-29.79%ROA24.25%Short Interest4.31MPerf YTD-9.89%
Book/sh-P/C3.22EPS next 5Y-11.83%ROE43.85%52W High21.04 -19.83%Perf Year52.30%
Cash/sh-P/FCF3.25EPS past 3/5Y-ROIC0.02%52W Low10.83 55.82%Perf 3Y75.63%
Dividend Est.-EV/EBITDA4.62Sales past 3/5Y28.02% 8.25%Gross Margin80.37%Volatility0.25% 0.53%Perf 5Y24.24%
Dividend TTM-EV/Sales6.00EPS Y/Y TTM291.30%Oper. Margin0.08%ATR (14)0.14Perf 10Y-24.26%
Dividend Ex-Date-Quick Ratio13.14Sales Y/Y TTM71.88%Profit Margin-RSI (14)50.50Recom2.94
Dividend Gr. 3/5Y-Current Ratio13.14EPS Q/Q43.41%SMA20-0.25%Beta0.19Target Price15.50
Payout0.00%Debt/Eq0.25Sales Q/Q20.00%SMA500.99%Rel Volume0.60Prev Close16.86
Employees90LT Debt/Eq0.22EarningsAug 11SMA200-1.13%Avg Volume587.21KPrice16.87
IPO DateMay 16, 2014Option/ShortYes / YesEPS/Sales Surpr.-443.57% -0.47%Net Debt/EBITDA-1.51Volume351,561Change0.06%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-07-26DowngradeHC Wainwright & Co.Buy → Neutral$15 → $17
Jun-29-26DowngradeJones TradingBuy → Hold
Jun-29-26DowngradeBTIGBuy → Neutral
Mar-05-26DowngradeOppenheimerOutperform → Perform
Mar-04-26DowngradeB. Riley SecuritiesBuy → Neutral$14
Dec-03-25InitiatedOppenheimerOutperform$27
Nov-26-25ReiteratedBTIGBuy$21 → $40
Nov-13-24ReiteratedLeerink PartnersMarket Perform$14 → $10
Aug-06-24DowngradeLeerink PartnersOutperform → Market Perform
Aug-06-24ReiteratedHC Wainwright & Co.Buy$15
Latest News
Jul-09-26
Jul-09-2603:00PM
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATKgurufocus.com
Jul-07-26
Jul-07-2607:41AM
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17Benzinga
Jul-01-26
Jul-01-2608:30AM
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharmaseekingalpha.com
Jun-30-26
Jun-30-2609:55AM
Theravance Stock Down 3% After Zymeworks Announces Buyoutzacks.com
Jun-29-26
Jun-29-2602:00PM
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)gurufocus.com
02:00PM
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?gurufocus.com
11:19AM
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.com
11:00AM
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholdersgurufocus.com
09:20AM
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisitionbenzinga.com
06:13AM
Zymeworks strikes $929 million deal for Theravance Biopharmareuters.com
06:00AM
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHTprnewswire.com
Company

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue11010764575155727360
Cost of Goods Sold Incl. D&A216384163194001
Gross Profit881022717-12-138727360
Selling, General and Administrative Excl. Other38746970679910910697
Research and Development3137384670202261219201
Other Operating Expense194-33-43-57-182-100
Operating Income1-13-47-56-92-258-298-252-239
Interest Expense32326993210
Unusual Expense
—————————
Non-Operating Income (Expense)139145596134223
Net Income Before Taxes137129-45-49-93-265-303-242-226
Income Taxes212312600-9-5-11
Consolidated Net Income115106-56-55872-199-278-236-216
Net Income From Continuing Operations115106-56-55-93-265-295-236-216
Net Income115106-56-55872-199-278-236-216
EPS (Recurring)2.262.10-1.15-1.00-1.26-2.87-4.46-4.25-3.99
EPS (Basic, Before Extraordinaries)2.262.10-1.15-1.00-1.26-2.87-4.46-4.25-3.99
EPS (Diluted)2.202.06-1.15-1.00-1.26-2.87-4.46-4.25-3.99
EBITDA142137-38-52-76-233-288-204-212
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio7.679.08———————
Price To Sales Ratio7.828.747.2010.8516.2813.8615.3019.8623.03
Gross Margin80.0095.3342.1929.82-23.53-250.91100.00100.00100.00
Operating Margin0.91-12.15-73.44-98.25-180.39-469.09-413.89-345.21-398.33
Net Margin104.5599.07-87.50-96.491,709.80-361.82-386.11-323.29-360.00
Shares Outstanding515049557469625654
Market Capitalization8609364616188307621,1021,4501,382
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$22.48$18.71$14.94$11.18$7.41● Close Price0.00M0.62M1.23M1.85M2.47MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSJun 15 '26Sale16.3913,314218,167232,457Jun 17
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSMar 16 '26Sale13.9631,067433,637232,699Mar 18
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSDec 03 '25Sale18.7531,067582,501277,695Dec 05
BROSHY ERANDirectorNov 26 '25Sale20.0029,501590,02044,703Dec 01
BROSHY ERANDirectorNov 26 '25Option Exercise10.1514,000142,10081,749Dec 01
BROSHY ERANDirectorNov 11 '25Sale18.05104,0001,877,50046,204Nov 14
BROSHY ERANDirectorNov 11 '25Option Exercise10.1514,000142,100107,878Nov 13
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSJul 14 '25Sale11.3910,000113,870326,918Jul 16
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSJun 02 '25Sale11.0024,000264,000336,918Jun 04
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSApr 21 '25Sale9.004,00036,000370,038Apr 23
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSJan 21 '25Sale9.004,00036,000309,565Jan 23
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSNov 11 '24Sale9.004,00036,000322,743Nov 13
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSJul 10 '24Sale9.004,00036,000335,965Jul 12
Samaha Eli10% OwnerMay 01 '24Buy8.751,499,12413,117,3358,511,350May 03
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSFeb 22 '24Sale8.711,25410,922311,733Feb 22
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.